Form 4: Carisma Therapeutics CFO Richard Morris Reports Stock Option Grant
SEC Filing (Form 4)
Richard Steven Morris, CFO of Carisma Therapeutics Inc., reports the acquisition of stock options.
Summary
- Richard Steven Morris, the Chief Financial Officer of Carisma Therapeutics Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on June 17, 2024.
- Morris acquired 85,000 stock options with an exercise price of $1.03.
- The options vest over two years, with 50% vesting on June 17, 2025, and the remaining 50% vesting on June 17, 2026, contingent upon continued service to Carisma Therapeutics Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a standard practice.
Positives
- The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with the long-term success of the company.
Key Dates
| Date | Description |
|---|---|
| 06/17/2024 | Date of stock option grant |
| 06/17/2025 | 50% of the shares underlying the option vest |
| 06/17/2026 | Remaining 50% of the shares underlying the option vest |
| 06/18/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.